who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

Amgen (AMGN) earnings date & Q3 2026 results

US GAAP · quarter ended 09/30/2026 · released Nov 3

Net income

$3,864M

up 20.1% y/y

Total revenues

$10,365M

up 8.5% y/y

Operating income

$3,710M

up 46.9% y/y

Next report

~ Feb 2

not announced yet

The quarter in brief

Amgen's Q3 2026 total revenues rose 8% to $10,365 million, and operating income rose 47% to $3,710 million. Net income grew 20% to $3,864 million and diluted EPS rose 19% from $5.93 to $7.08.

Key growth driver: Revenue growth of +9% y/y — the report gives no segment split, so the driver is the whole business. · by the Q3 2026 report

All figures in $M.

Sankey diagram of AMGN (Amgen) earnings report for Q3 2026: revenue, costs and profitProduct sales$9,883 · +8.2%Other revenues$482 · +14.8%Total revenues$10,365 · +8.5%Cost of sales$2,788 · −9.5%Research anddevelopment$2,111 · +11.1%Selling, generalandadministrative$1,680 · −2.3%Other$76 · −76.9%Operating income$3,710 · +46.9%35.8% marginInterest expense,net$653 · −4.7%Other income, net$1,629 · −21.7%Income beforeincome taxes$4,686 · +19.5%Provision for income taxes$822 · +16.6%17.5% effective rateNet income$3,864 · +20.1%$7.08/sh · 37.3% margin
Sankey diagram of AMGN (Amgen) earnings report for Q3 2026: revenue, costs and profit
Line itemAmount and change
Product sales$9,883 · +8.2%
Other revenues$482 · +14.8%
Total revenues$10,365 · +8.5%
Cost of sales$2,788 · −9.5%
Research and development$2,111 · +11.1%
Selling, general and administrative$1,680 · −2.3%
Other$76 · −76.9%
Operating income$3,710 · +46.9% · 35.8% margin
Interest expense, net$653 · −4.7%
Other income, net$1,629 · −21.7%
Income before income taxes$4,686 · +19.5%
Provision for income taxes$822 · +16.6% · 17.5% effective rate
Net income$3,864 · +20.1% · $7.08/sh · 37.3% margin

Verdict: Amgen's Q3 2026 total revenues rose 8% to $10,365 million, and operating income rose 47% to $3,710 million. Net income grew 20% to $3,864 million and diluted EPS rose 19% from $5.93 to $7.08.

For full-year 2026 Amgen expects total revenues of $38.9–39.7 billion, GAAP EPS of $18.34–19.28 and non-GAAP EPS of $22.90–23.70. It expects capital expenditures of about $2.6 billion and share repurchases not exceeding $3.0 billion, after no repurchases in Q3 2026. The Q3 dividend was $2.52 per share, up 6% year over year. Free cash flow was $3.7 billion versus $4.2 billion a year earlier.

Source and notation

Source: Amgen press release, 8-K EX-99.1 of 11/03/2026 (SEC EDGAR).

Open as an image: Amgen (AMGN), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “Amgen (AMGN) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/amgn. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/amgn"><img src="https://whoreportstoday.com/t/amgn/img/amgen-amgn-earnings-sankey.png" alt="Amgen (AMGN) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/amgn">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/amgn/img/amgen-amgn-earnings-sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/amgn">Amgen (AMGN) Q3 2026 earnings chart (Who Reports Today)</a>

The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. · Text: Wikipedia, CC BY-SA 4.0, abridged

The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. Market share (US pharma & biotech): ≈5% by TTM revenue.

Company reports

Q3 2026latest breakdownAmgen's Q3 2026 total revenues rose 8% to $10,365 million, and operating income rose 47% to $3,710 million. Net income…
Q2 2026Revenue rose 9.5% to $10.1B and net income 65.9% to $2.4B — but the profit jump is mostly the fading of acquisition…

Company guidance

PeriodCompany guidanceA year agoImplied growth
FY2026revenue $38.9–39.7BEPS (GAAP) $18.34–19.28EPS (non-GAAP) $22.90–23.70revenue $36.75BEPS (GAAP) $14.23revenue +6…8%EPS (GAAP) +29…35%

Same quarter a year ago (ended December 31, 2025): revenue $9.87B, EPS (GAAP) $2.45

How we calculate

Implied growth compares the low and high ends of the company's range with the same period a year ago (midpoint: +7%).

EPS growth is not calculated: the guidance is non-GAAP (adjusted), while the year-ago EPS is GAAP, so the two are not comparable.

Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.

Guidance comes from the company's earnings release (Form 8-K filed Nov 3, 2026); every figure is checked against the release text.

The company's release on SEC EDGAR (8-K exhibit) ↗

AMGN earnings history: past report dates

Nov 3, 2026 Tue4:05 pmafter market closeSep 30, 2026$10.4B+8% y/y$7.08+19% y/y
Aug 4, 2026 Tue4:03 pmafter market closeJun 30, 2026$10.1B+10% y/y$4.37+65% y/y
Apr 30, 2026 Thu4:03 pmafter market closeMar 31, 2026$8.6B+6% y/y$3.34+4% y/y
Feb 3, 2026 Tue4:03 pmafter market closeDec 31, 2025≈$9.9B+9% y/y≈$2.45+109% y/y
Nov 4, 2025 Tue4:04 pmafter market closeSep 30, 2025$9.6B+12% y/y$5.93+14% y/y
Aug 5, 2025 Tue4:03 pmafter market closeJun 30, 2025$9.2B+9% y/y$2.65+92% y/y
May 1, 2025 Thu4:04 pmafter market closeMar 31, 2025$8.1B+9% y/y$3.20
Feb 4, 2025 Tue4:05 pmafter market closeDec 31, 2024≈$9.1B+11% y/y≈$1.17−18% y/y
Oct 30, 2024 Wed4:06 pmafter market closeSep 30, 2024$8.5B+23% y/y$5.22+62% y/y
Aug 6, 2024 Tue4:05 pmafter market closeJun 30, 2024$8.4B+20% y/y$1.38−46% y/y
May 2, 2024 Thu4:03 pmafter market closeMar 31, 2024$7.4B+22% y/y−$0.21
Feb 6, 2024 Tue4:20 pmafter market closeDec 31, 2023≈$8.2B+20% y/y≈$1.42−53% y/y
Oct 31, 2023 Tue7:15 ambefore market openSep 30, 2023$6.9B+4% y/y$3.22−19% y/y
Aug 3, 2023 Thu4:12 pmafter market closeJun 30, 2023$7.0B+6% y/y$2.57+5% y/y
Apr 27, 2023 Thu4:11 pmafter market closeMar 31, 2023$6.1B−2% y/y$5.28+97% y/y
Jan 31, 2023 Tue4:15 pmafter market closeDec 31, 2022≈$6.8B−0% y/y≈$3.00−10% y/y
Show all 16 reports since 2023Show fewer
How we count

Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.

Amgen: 15-year financials

202536,7519,0807,7118,1005,124
202433,4247,2584,09010,3944,832
202328,1907,8976,7177,3594,556
202226,3239,5666,5528,7854,196
202125,9797,6395,8938,3814,013
202025,4249,1397,2649,8893,755
201923,3629,6747,8428,5323,509
201823,74710,2638,39410,5583,507
201722,8499,9731,97910,5133,365
201622,9919,7947,7229,6162,998
201521,6628,4706,9399,1372,396
201420,0636,1915,1588,2341,851
201318,6765,8675,0815,5981,415
201217,2655,5774,3455,1931,118
201115,5824,3123,6834,552500

$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.

* Sources
How we calculate

Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.

Amgen: 15-year balance sheet

YearAssetsEquityDebtCashCurrent assetsCurrent liabilities
202590,5868,65854,6049,12929,05725,489
202491,8395,87760,09911,97329,03023,099
202397,1546,23264,61310,94430,33218,392
202265,1213,66138,9457,62922,18615,687
202161,1656,70033,3097,98919,38512,184
202062,9489,40932,9866,26621,14411,653
201959,7079,67329,9036,03718,44012,835
201866,41612,50033,9296,94537,61813,488
201779,95425,24135,3423,80049,4769,020
201677,62629,87534,5963,24146,01011,204
201571,44928,08331,4294,14438,5158,664
201469,00925,77830,7153,73134,7137,008
201366,12522,09632,1283,80527,3677,947
201254,29819,06026,5293,25731,2098,191
201148,87119,02921,4286,94627,5935,754

$ millions, at fiscal year-end*.

* Sources
How we calculate

Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .

Cash flow

9 months ended 2026-09-30 · $M

LineThis periodYear agoΔ
Operating cash flowcash the business generated10,4328,355+2,077
· incl. D&A (non-cash add-back)depreciation & amortization3,3504,035
· incl. stock-based comp (non-cash)share-based compensation368369
Capexpurchases of property & equipment−1,812−1,216−596
Free cash flow ≈operating cash flow − capex8,6207,139+1,481
Investing activities, netcapex, acquisitions, securities−1,934−1,250−684
Financing activities, netdebt, buybacks, dividends−4,437−9,633+5,196
· incl. dividends paid−4,083−3,841−242
Net change in cash4,061−2,528+6,589
How to read the table

Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.

Shareholders’ equity at Sep 30, 2026: $14.4B (15% of total assets). Compare with other S&P 500 companies →

Corporate governance

1.5/2mostly good

  • Oct 2016The court granted final approval of the settlement in In re Amgen Inc. Securities Litigation (a suit over 2004–2007 statements on Aranesp/Epogen; the $95M amount was announced in 07/2016). sec.gov ↗
  • Feb 2026The 2025 10-K discloses an unresolved class action, Roofers Local No. 149 (2023), over disclosure of a tax dispute with the IRS. sec.gov ↗
1 more fact and scoring

How the company treats minority shareholders: 2 — well, 0 — systematically poorly.

  • Dec 2025Diluted shares −8% over 2020–2025; SBC of $0.49B = 1.3% of revenue; the dividend rose from $6.56 to $9.66 per share. data.sec.gov ↗

Scoring: 2.0 −0.5 (criterion 9: investor suit over Aranesp/Epogen settled for $95M; settlement approved by the court in Oct 2016, within 10 years) = 1.5

Share classes
Single class of common stock (2025 10-K cover).
Dilution
Diluted shares −8% over 2020–2025, SBC 1.3% of revenue.
Disclosure
Full US GAAP reporting: 10-K and 10-Q filed on EDGAR on time.
Dividends
Dividend raised every year ($6.56 → $9.66 over 2020–2025); buybacks were nearly absent in 2023–2025 after the all-cash Horizon acquisition — no buyback commitments, no deduction.
Lawsuits & regulators
2007 investor suit (Aranesp/Epogen) settled for $95M, court approval in Oct 2016 — full deduction; the Roofers suit (2023, IRS tax dispute) and derivative suits are unresolved — no deduction.
Related parties
The 2026 proxy lists only a senior executive's son-in-law on staff (~$0.37M) — immaterial.

How the score works · checked as of Oct 2026

Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap

Amgen (AMGN) earnings: FAQ

When is AMGN's next earnings date?

We have not yet seen an announcement of the date from Amgen (AMGN). Based on last year's report on Feb 3, 2026, the next report is expected around Feb 2, 2027.

What time does AMGN report earnings?

Amgen usually reports after market close: its latest results release was filed with the SEC at 4:05 pm ET on Nov 3, 2026.

When did AMGN last report earnings?

Amgen reported Q3 2026 results on Nov 3, 2026.

What has Amgen guided for FY2026?

Company guidance for FY2026: revenue $38.9–39.7B; EPS (GAAP) $18.34–19.28; EPS (non-GAAP) $22.90–23.70. A year ago (FY2025): revenue $36.75B, EPS (GAAP) $14.23. Implied growth: revenue +6…8%, EPS (GAAP) +29…35%. Source: the company's earnings release (Form 8-K filed Nov 3, 2026).

Where can I find Amgen's financial statements?

On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to AMGN's filings; this page breaks the latest report down in a Sankey chart.

What was AMGN's net income in Q3 2026?

Amgen reported net income of $3,864M for Q3 2026 (+20.1% year over year), under US GAAP.

Does Amgen pay dividends?

Yes. In 2025, Amgen paid $5,124M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.

How has Amgen's revenue changed since 2011?

Per its 10-K filings, revenue grew 2.4x: $15,582M in 2011 and $36,751M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.

New to earnings reports? Start with how to read an earnings report.

Get it every Monday: who reports this week

Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.

Only dates announced by companies. No stock prices. Not investment advice.

More reports: BAX · Q3 2026 · BDX · Q4 FY2026 · BIIB · Q3 2026 · BMY · Q3 2026 · BSX · Q3 2026 · CAH · Q1 FY2027 · CI · Q3 2026 · CNC · Q3 2026 · COO · Q3 FY2026 · COR · Q4 FY2026 · all reports

Cookies the site needs and, with your consent, Google Analytics — privacy policy